Pulmatrix (PULM)
NASDAQ:PULM
Want to see PULM full AI Analyst Report?
Top Page
Pulmatrix
(NASDAQ:PULM)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.50
▼(-36.17% Downside)
Action:Reiterated
Date:05/16/26
The score is held down primarily by weak financial performance (no sustained revenue, ongoing losses, and continued cash burn) and bearish technicals (below key moving averages with negative MACD). Corporate events provide some upside optionality via the planned merger and financing, but deal execution risk and the absence of valuation support keep the overall score low.
Positive Factors
Low Leverage
No formal debt obligations reduce fixed financial burden and default risk, important for a clinical-stage biotech. Over the next 2–6 months this enhances flexibility to fund trials or integrate merger proceeds without immediate interest costs, lowering downside in stressed funding scenarios.
Negative Factors
No Sustained Revenue
Absence of recurring product revenue means the firm's value and continuity depend on capital markets and successful clinical/regulatory progress. Over 2–6 months, lack of commercial cash inflows raises execution risk and magnifies reliance on merger financing and external investors.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
No formal debt obligations reduce fixed financial burden and default risk, important for a clinical-stage biotech. Over the next 2–6 months this enhances flexibility to fund trials or integrate merger proceeds without immediate interest costs, lowering downside in stressed funding scenarios.
Read all positive factors
Pulmatrix (PULM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.11M
Dividend YieldN/A
Average Volume (3M)7.19K
Price to Earnings (P/E)―
Beta (1Y)-0.27
Revenue Growth-100.00%
EPS Growth62.88%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.23
Shares Outstanding3,652,285
10 Day Avg. Volume4,700
30 Day Avg. Volume7,194
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.14
Price to Sales (P/S)0.00
P/FCF Ratio-1.50
Enterprise Value/Market Cap0.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-125.19
Enterprise Value/Ebitda-0.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.24
Revenue Forecast (FY)$16.45M
Pulmatrix Business Overview & Revenue Model
Company Description
Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States...
How the Company Makes Money
null...
Pulmatrix Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 7.81M | 7.30M | 6.07M | 5.17M |
| Gross Profit | -14.00K | 0.00 | 640.00K | -8.22M | -12.17M | -10.21M |
| EBITDA | -4.50M | -5.16M | -7.04M | -13.99M | -18.67M | -16.42M |
| Net Income | -4.53M | -5.16M | -9.56M | -14.12M | -18.84M | -20.17M |
Balance Sheet | ||||||
| Total Assets | 4.50M | 4.14M | 9.94M | 33.96M | 40.95M | 58.82M |
| Cash, Cash Equivalents and Short-Term Investments | 3.32M | 4.09M | 9.52M | 19.17M | 35.63M | 53.84M |
| Total Debt | 0.00 | 0.00 | 0.00 | 8.76M | 857.00K | 2.29M |
| Total Liabilities | 905.00K | 329.00K | 996.00K | 15.96M | 9.84M | 11.37M |
| Stockholders Equity | 3.59M | 3.81M | 8.95M | 18.00M | 31.11M | 47.45M |
Cash Flow | ||||||
| Free Cash Flow | -4.69M | -5.43M | -11.11M | -16.66M | -19.44M | -19.87M |
| Operating Cash Flow | -4.69M | -5.43M | -10.72M | -15.98M | -19.36M | -19.73M |
| Investing Cash Flow | 0.00 | 0.00 | -398.00K | -676.00K | -86.00K | -144.00K |
| Financing Cash Flow | 1.00M | 0.00 | 0.00 | 53.00K | 1.23M | 43.48M |
Pulmatrix Technical Analysis
Positive
2.35
Price Trends
1.31
Positive
1.83
Negative
3.03
Negative
Market Momentum
<0.01
Negative
55.44
Neutral
49.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PULM, the sentiment is Positive. The current price of 2.35 is above the 20-day moving average (MA) of 1.34, above the 50-day MA of 1.31, and below the 200-day MA of 3.03, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.44 is Neutral, neither overbought nor oversold. The STOCH value of 49.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PULM.
Pulmatrix Risk Analysis
Pulmatrix disclosed 73 risk factors in its most recent earnings report. Pulmatrix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pulmatrix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $11.88M | -1.77 | -89.92% | ― | ― | 63.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $18.63M | -1.34 | -66.69% | ― | -45.52% | -94.82% | |
44 Neutral | $7.83M | -2.01 | -49.00% | ― | 11.90% | 43.46% | |
43 Neutral | $5.11M | -1.13 | -79.47% | ― | -100.00% | 62.88% | |
42 Neutral | $83.96M | -7.32 | -53.86% | ― | -20.00% | 75.26% | |
42 Neutral | $4.85M | -0.11 | -1292.87% | ― | ― | -72.78% |
* Healthcare Sector Average
PULM
Pulmatrix
1.40
-7.30
-83.91%
IBIO
Ibio
1.69
0.82
93.36%
LPCN
Lipocine
2.26
-0.80
-26.14%
IMRN
Immuron
1.19
-0.59
-33.15%
CMMB
Chemomab Therapeutics
1.65
-3.27
-66.46%
FBLG
FibroBiologics, Inc.
0.93
-15.01
-94.16%
Pulmatrix Corporate Events
M&A TransactionsPrivate Placements and Financing
Pulmatrix Raises $1M in Preferred Stock Financing
Positive
Apr 21, 2026
On April 16, 2026, Pulmatrix closed a $1 million private placement of Series B Convertible Preferred Stock with an affiliate of Eos SENOLYTIX at a conversion price of $2.20 per share, a transaction announced on April 21, 2026 as part of the planne...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Pulmatrix to Merge With Eos SENOLYTIX, Rebrand on Nasdaq
Positive
Mar 27, 2026
On March 26, 2026, Pulmatrix agreed to acquire Eos SENOLYTIX in an all-stock merger that will leave pre-merger Eos investors owning about 94% of the combined company, which will be renamed Eos SENOLYTIX, Inc. and is expected to continue trading on...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.